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During the past two decades, there has been an altered 
epidemiologic scenario for measles. There have been 
many outbreaks affecting adolescents, young adults, 
and infants below 6 months of age. The disease profile 
has been addressed by offering more than one dose 
of vaccine in routine immunization. Alternatively, in 
different parts of North and South America, measles 
vaccination strategies have consisted of catch-up, keep- 
up and follow-up campaigns1 Usually, such strategies 
against measles have involved children 1-14 years 
of age. Although measles virus does infect pregnant 
women, neonates and young infants, live measles 
vaccines with potential adverse effects on the fetus have 
not been employed in pregnant females. 
An outbreak of measles involved pregnant women 
in Burkina Faso. The clinical manifestations in 16 
infected mothers, with mean age, gravidity and parity of 
20.6 years, 2.1 and 1.1, respectively, included six cases 
of laryngitis, three cases of pneumonitis, two abortions, 
three stillbirths, and one preterm delivery.2 In Saudi 
Arabia, pneumonia, fever and high prematurity accom- 
panied measles in 40 pregnant females3 Furthermore, 
infants below 6 months of age also suffer from measles. 
Measles virus was isolated from 192 infants aged less 
than 6 months and 44 infants aged less than 4 months at 
the University Teaching Hospital at Lusaka, Zambia.4 
There was unequivocal evidence of measles in four 
4-month-old infants in an orphanage. Measles virus was 
isolated from such orphans at Pune, in India.5 
Ideally, any measles mortality or morbidity during 
pregnancy would be best tackled through identification 
of every susceptible seronegative woman. Simple pro- 
cedures for quantification of measles virus-specific IgG 
(mIgG) that do not require costly equipment or trained 
personnel but could be carried out in obstetricians’ 
premises would be an invaluable asset in this connection. 
Initial laboratory data have indicated that antibody 
assays with sensitized gelatin particles that are aggluti- 
nated by measles virus hemagglutinin and fusion protein 
antibody are as sensitive as the plaque neutralization 
test.6 Likewise, use of saliva samples rather than serum 
samples for quantification of measles virus-specific IgM7 
appears to be satisfactory. Their identical field perform- 
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ante should simplify the specific diagnosis of measles, 
including its complications. 
Moreover, any susceptibility to measles virus could 
be assayed concurrently during an identical screening 
for rubella. The susceptible women who were not preg- 
nant or not planning to get pregnant for at least 1 month 
could be given measles-mumps-rubella vaccine. Alter- 
natively, a second dose of measles virus vaccine could 
be given to someone who was neither pregnant nor 
planning a pregnancy. The cost of immunoglobulin 
might be prohibitive for susceptible pregnant women in 
endemic areas in poor countries. Certainly, they could be 
immunized immediately after childbirth. 
To conclude, the use of measles vaccine or immuno- 
globulin in women in childbearing age or the early 
postpartum periods would be cost-effective. Pre-travel 
immunization would also be appropriate in women 
traveling from measles-free countries to measles- 
endemic areas. The pre-travel vaccine should protect 
women in the event of a pregnancy while they are in 
measles-endemic areas. 
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